Zika Vaccine Candidate Conducts Discussion

Valneva SE announced today it would host a roundtable on Zika virus vaccines at the 23rd World Vaccine Congress in Washington, D.C.

On April 4, 2023, Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, MD, will host a roundtable discussion on the opportunities and challenges of a Zika vaccine.

Valneva successfully developed an inactivated whole-virus Zika vaccine candidate VLA1601 through a Phase 1 clinical trial, which was last updated on July 5, 2019.

The company is evaluating re-entry into clinical development later in 2023 or 2024.

VLA1601 is a purified, inactivated, whole Zika virus vaccine candidate adsorbed on aluminum hydroxide.

As of March 30, 2023, no approved Zika vaccines are available in the U.S.